Attorney Docket No.: PB60589USw

REMARKS

Claims 1-14 are presented in this application. In this amendment, claims 3-10, 13, and 14 have been amended to place them in form appropriate to US practice and to remove multiple dependencies for the purpose of reducing fees.

Applicants have amended the specification for purposes of adding the priority information. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

ďameks P. Rìeḱ

Attorney for Applicant Registration No. 39,009

Date: 7 1 / 200 le

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive

P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919

919-483-8022

Facsimile: 919-483-7988